Skip to content
NoBlaBlaFinance
FilingsCompaniesSectorsCalendar
Log inFrançais
Inside informationEnglish

Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Sanofi

The file is served by the AMF. We do not host a copy.

Document type

Issuer
Sanofi
Filed
13/04/2026, 07:00
Document type
Inside information
AMF sub-type
Informations privilégiées
Language
English
AMF reference
115337_20260413